Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242254 | 0.84 | CHRM3 (0.48) | CHRM3CHRM2CHRM4CHRM1SMN1; SMN2 | |
| SCHEMBL4241540 | 0.84 | CHRM3 (0.51) | CHRM3CHRM2CHRM4CHRM1SMN1; SMN2 | |
| SCHEMBL2655676 | 0.84 | CHRM3 (0.64) | CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL3554824 | 0.84 | CHRM3 (0.44) | CHRM3CHRM2CHRM4CHRM1POLB | |
| SCHEMBL4208886 | 0.84 | CHRM3 (0.64) | CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL4245314 | 0.81 | CHRM3 (0.60) | CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL12696308 | 0.81 | CHRM3 (0.44) | CHRM3CHRM2CHRM4CHRM1SMN1; SMN2 | |
| SCHEMBL4245374 | 0.81 | NPC1 (0.47) | CHRM3CHRM2CHRM4CHRM1 | |
| SCHEMBL4240159 | 0.80 | CHRM3 (0.54) | CHRM3CHRM2CHRM4CHRM1SLC6A3 | |
| SCHEMBL13701471 | 0.80 | CHRM3 (0.78) | CHRM3CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727998-B2 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2013172-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007123465-A1 | NEW ALKYL ESTERS OF CYCLIC AMINO ALCOHOLS WITH MUSCARINIC M3 RECEPTOR ANTAGONIST ACTIVITY, USEFUL FOR TREATING E.G. CHRONIC BRONCHIAL OBSTRUCTION, ASTHMA AND OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1595867-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233965-A1 | Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM4 5/4885 |
| US-20060106046-A1 | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient | MCHR1, MC1R, PRLHR | CHRM3 245/4885CHRM2 185/4885CHRM4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.